Clinical Trial Update: Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia. [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of an oral minoxidil formulation (N1087) in men with androgenetic alopecia; study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• Oral Minoxidil (N1087) (minoxidil)

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Androgenetic Alopecia, Androgenetic Alopecia (AGA) | Phase 3 | Status: NOT_YET_RECRUITING